Advanced Filters
noise
Found 638 clinical trials
M Morgan Bean

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

18 years of age All Phase N/A
X Xiaofei Zhu

Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)

In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.

18 - 75 years of age All Phase 2
W Weijing Zhang

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety …

18 - 75 years of age All Phase 2
B BoYongShen

HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

18 - 80 years of age All Phase 2
R Research Referral Office

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.

18 years of age All Phase 2
J Juan Du, PhD

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.

18 - 75 years of age All Phase 2
J Jiang Long, MD

PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.

This study will collect patient PRO (physical strength, pain, defecation, appetite, weight, etc.) data through the APP, use corpus collection cards, facial photography and other technologies to collect PGHD characteristic phenotypes, and then combine artificial intelligence technology to train and cultivate agents (agents) to carry out joint offline routine follow-up …

18 - 80 years of age All Phase N/A
Y Yanfang Liu, MD PhD

CAR-NK Cells (CL-NK-001) in Pancreatic Cancer

This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.

18 - 70 years of age All Phase 1

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Pancreatic cancer is a deadly disease and will be the second leading cause of cancer related death behind lung cancer by 2030. Over 62,000 people are diagnosed each year in the United States with about 90% succumbing to the disease within 5 years. In the metastatic setting, NALIRIFOX, FOLFIRINOX and …

18 years of age All Phase 1/2
J Junjie Hang, M.D.

Irinotecan Liposome in Combination With Capecitabine

Pancreatic cancer is a group of malignant tumors mainly originated from pancreatic ductal epithelium and follicular cells, with high degree of malignancy, insidious onset, difficult early diagnosis, rapid progression, short survival time, and one of the malignant tumors with the worst prognosis, which is known as the "king of cancers". …

18 - 80 years of age All Phase N/A

Simplify language using AI